| Identification | Back Directory | [Name]
ML-327 | [CAS]
1883510-31-3 | [Synonyms]
-327
ML-327
ML327;ML-327;ML 327
3-Pyridinecarboxamide, 1,2-dihydro-2-oxo-N-[3-[[(5-phenyl-3-isoxazolyl)carbonyl]amino]propyl]- | [Molecular Formula]
C19H18N4O4 | [MOL File]
1883510-31-3.mol | [Molecular Weight]
366.37 |
| Hazard Information | Back Directory | [Uses]
ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT). | [Biological Activity]
ML327 is a regulator of E-cadherin transcription th at restores E-cadherin expression in cancer cell lines and partially reverses Epithelial-to-Mesenchymal Transition (EMT). It is a potent inducer of mesenchymal-to-epithelial transition (MET) in epithelial cancers. Apparently ML327 blocks MYC expression in neuroblastomas. It induces apoptosis in cancer cells and sensitizes Ewing sarcoma cells to TRAIL. | [in vivo]
ML327 treatment significantly reduces tumor volume by three-fold over the two-week treatment period (p=0.02). Tumor explant weights are approximately three-fold smaller in the ML327-treated mice (p=0.01). Mice treated with ML327 lost 12% more body weight than vehicle treated mice. ML327 treatment results in a two-fold decrease in MYCN expression, confirming that ML327 inhibits xenograft MYCN expression (p=0.0035)[1]. | [storage]
Store at -20°C |
|
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|